These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 27143351)

  • 1. Impact of clinical pharmacy services on outcomes and costs for indigent patients with diabetes.
    Quinones ME; Pio MY; Chow DH; Moss E; Hulstein JL; Boatright SM; Mathew A
    Am J Manag Care; 2016 Apr; 22(4):e147-52. PubMed ID: 27143351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
    J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes mellitus medication assistance program: relationship of effectiveness to adherence.
    Horswell RL; Wascom CK; Cerise FP; Besse JA; Johnson JK
    J Health Care Poor Underserved; 2008 Aug; 19(3):677-86. PubMed ID: 18677064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database.
    Kirkman MS; Rowan-Martin MT; Levin R; Fonseca VA; Schmittdiel JA; Herman WH; Aubert RE
    Diabetes Care; 2015 Apr; 38(4):604-9. PubMed ID: 25573883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between continuity of ambulatory care and medication adherence in adult patients with type 2 diabetes in Korea: a longitudinal analysis.
    Hong JS; Kang HC
    Med Care; 2014 May; 52(5):446-53. PubMed ID: 24714582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost sharing, adherence, and health outcomes in patients with diabetes.
    Gibson TB; Song X; Alemayehu B; Wang SS; Waddell JL; Bouchard JR; Forma F
    Am J Manag Care; 2010 Aug; 16(8):589-600. PubMed ID: 20712392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of diabetes medication adherence and healthcare costs in patients using mail order pharmacy and retail pharmacy.
    Devine S; Vlahiotis A; Sundar H
    J Med Econ; 2010; 13(2):203-11. PubMed ID: 20345227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and economic impact of a diabetes clinical pharmacy service program in a university and primary care-based collaboration model.
    Monte SV; Slazak EM; Albanese NP; Adelman M; Rao G; Paladino JA
    J Am Pharm Assoc (2003); 2009; 49(2):200-8. PubMed ID: 19289346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007; 29 Spec No():1294-305. PubMed ID: 18046929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Mississippi Delta Health Collaborative Medication Therapy Management Model: Public Health and Pharmacy Working Together to Improve Population Health in the Mississippi Delta.
    Ross LA; Bloodworth LS; Brown MA; Malinowski SS; Crane R; Sutton V; Karimi M; Dove Brown AC; Dobbs T; Hites L
    Prev Chronic Dis; 2020 Sep; 17():E108. PubMed ID: 32945767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial.
    Lee JK; Grace KA; Taylor AJ
    JAMA; 2006 Dec; 296(21):2563-71. PubMed ID: 17101639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.
    Ayyagari R; Wei W; Cheng D; Pan C; Signorovitch J; Wu EQ
    Value Health; 2015 Mar; 18(2):198-205. PubMed ID: 25773555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care.
    Virani SS; Wang D; Woodard LD; Chitwood SS; Landrum CR; Zieve FJ; Ballantyne CM; Petersen LA
    J Clin Lipidol; 2012; 6(6):545-52. PubMed ID: 23312050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia.
    Bunting BA; Smith BH; Sutherland SE
    J Am Pharm Assoc (2003); 2008; 48(1):23-31. PubMed ID: 18192127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes.
    Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ
    Clin Interv Aging; 2015; 10():991-1001. PubMed ID: 26124652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes pharmacy management: balancing safety, cost, and outcomes.
    Dunn JD
    Am J Manag Care; 2010 Aug; 16(7 Suppl):S201-6. PubMed ID: 20809669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a medication assistance program on health outcomes in patients with type 2 diabetes mellitus.
    Strum MW; Hopkins R; West DS; Harris BN
    Am J Health Syst Pharm; 2005 May; 62(10):1048-52. PubMed ID: 15901589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic rationale for adherence in the treatment of type 2 diabetes mellitus.
    Wild H
    Am J Manag Care; 2012 Apr; 18(3 Suppl):S43-8. PubMed ID: 22558941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.